FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164382916> ?p ?o ?g. }

• W3164382916 endingPage "615" @default.
• W3164382916 startingPage "614.2" @default.
• W3164382916 abstract "Background: Immunosuppressive therapy increases the risk of pneumococcal infection in patients with systemic lupus erythematosus (SLE). The therapy, as well as some features of the course of the disease, can lead to a decrease in the immunogenicity of the pneumococcal vaccine in these patients. Objectives: The aim of the study was to identify “risk factors” that negatively affect the immunogenicity of the 23-valent polysaccharide pneumococcal vaccine (PPV-23) in patients with SLE. Methods: The study included 60 patients aged 19 - 68 years with a reliable diagnosis of SLE, disease duration from 9 months. up to 42 years old. Nine patients had high disease activity, 12 had medium, 33 had low, and 6 had remission. Therapy: 58 patients received glucocorticoids (GC) 5-40 mg / day, 46-hydroxychloroquine, 33- cytostatics (CS), 23- biologics: 12-rituximab (RTM), 10-belimumab (BLM), 1- RTM and BLM. 1 dose (0.5 ml) of PPV-23 was administered subcutaneously. During the year, standard clinical and laboratory studies were carried out, the level of antibodies to polysaccharides of the S. pneumoniae cell wall in the blood serum was determined. Results: After 1-2 months. after vaccination, 78.7% of patients showed a more than twofold increase in protective antibodies, a year later - in 56.7% of patients (“responders”). The severity of the vac-cine response did not depend on age: in the subgroup of patients under 50 years of age (n = 46), the proportion of “responders” remained 52.2%, and in patients over 50 years of age (n = 14) -50%. With different duration of the disease, the vaccine response did not differ significantly: with a disease period of up to 5 years, the vaccine response was observed in 47.6%, from 5 to 10 years - in 66.7%, over 10 years - in 55.6% of patients. Patients in remission had the lowest vaccine response (33.3%), while with high SLE activity, 100% response to the vaccine was recorded (p = 0.02), which is probably due to the fact that remission requires long-term and active immunosuppressive therapy, and patients with high activity such therapy has just been initiated or is to be. With an average and low degree of activity, the number of “respondents” was the same (50% and 51.5%, respectively). In patients receiving biologics therapy, a full-fledged vaccine response was observed less frequently than in patients without biologics (39% and 68%, respectively, p = 0.03), while no differences were found against the background of RTM and BLM therapy (41.6% and 40% of “respondents”, respectively). The effect of the duration of biologics therapy on the severity of the vaccine response was analyzed. There was a tendency for the predominance of “responders” in the group with a duration of therapy before vaccination up to 1 year, as well as in the group of initiation of biologics after vaccination, however, the differences were not statistically significant. Conclusion: RTM and BLM have a negative effect on the immunogenicity of the PPV-23 vaccine. However, if the timing of administration is observed (initiation of biologics therapy after vaccination or vaccination against the background of biologics therapy lasting less than a year), the number of “responders” increases. Further recruitment of patients is needed to clarify and confirm the results obtained. Disclosure of Interests: None declared" @default.
• W3164382916 created "2021-06-07" @default.
• W3164382916 creator A5022891077 @default.
• W3164382916 creator A5025976331 @default.
• W3164382916 creator A5037294287 @default.
• W3164382916 creator A5062634527 @default.
• W3164382916 creator A5072166059 @default.
• W3164382916 creator A5073493598 @default.
• W3164382916 creator A5079352743 @default.
• W3164382916 date "2021-05-19" @default.
• W3164382916 modified "2023-10-14" @default.
• W3164382916 title "POS0729 INFLUENCE OF VARIOUS FACTORS ON THE IMMUNOGENICITY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS" @default.
• W3164382916 doi "https://doi.org/10.1136/annrheumdis-2021-eular.1445" @default.
• W3164382916 hasPublicationYear "2021" @default.
• W3164382916 type Work @default.
• W3164382916 sameAs 3164382916 @default.
• W3164382916 citedByCount "0" @default.
• W3164382916 crossrefType "journal-article" @default.
• W3164382916 hasAuthorship W3164382916A5022891077 @default.
• W3164382916 hasAuthorship W3164382916A5025976331 @default.
• W3164382916 hasAuthorship W3164382916A5037294287 @default.
• W3164382916 hasAuthorship W3164382916A5062634527 @default.
• W3164382916 hasAuthorship W3164382916A5072166059 @default.
• W3164382916 hasAuthorship W3164382916A5073493598 @default.
• W3164382916 hasAuthorship W3164382916A5079352743 @default.
• W3164382916 hasBestOaLocation W31643829161 @default.
• W3164382916 hasConcept C126322002 @default.
• W3164382916 hasConcept C159654299 @default.
• W3164382916 hasConcept C170286685 @default.
• W3164382916 hasConcept C203014093 @default.
• W3164382916 hasConcept C22070199 @default.
• W3164382916 hasConcept C2778453870 @default.
• W3164382916 hasConcept C2779123688 @default.
• W3164382916 hasConcept C2779134260 @default.
• W3164382916 hasConcept C2779301066 @default.
• W3164382916 hasConcept C2779664119 @default.
• W3164382916 hasConcept C2780653079 @default.
• W3164382916 hasConcept C2780868878 @default.
• W3164382916 hasConcept C2781205201 @default.
• W3164382916 hasConcept C2781253189 @default.
• W3164382916 hasConcept C3008058167 @default.
• W3164382916 hasConcept C3020803494 @default.
• W3164382916 hasConcept C501593827 @default.
• W3164382916 hasConcept C524204448 @default.
• W3164382916 hasConcept C71924100 @default.
• W3164382916 hasConcept C86803240 @default.
• W3164382916 hasConcept C89423630 @default.
• W3164382916 hasConcept C90924648 @default.
• W3164382916 hasConceptScore W3164382916C126322002 @default.
• W3164382916 hasConceptScore W3164382916C159654299 @default.
• W3164382916 hasConceptScore W3164382916C170286685 @default.
• W3164382916 hasConceptScore W3164382916C203014093 @default.
• W3164382916 hasConceptScore W3164382916C22070199 @default.
• W3164382916 hasConceptScore W3164382916C2778453870 @default.
• W3164382916 hasConceptScore W3164382916C2779123688 @default.
• W3164382916 hasConceptScore W3164382916C2779134260 @default.
• W3164382916 hasConceptScore W3164382916C2779301066 @default.
• W3164382916 hasConceptScore W3164382916C2779664119 @default.
• W3164382916 hasConceptScore W3164382916C2780653079 @default.
• W3164382916 hasConceptScore W3164382916C2780868878 @default.
• W3164382916 hasConceptScore W3164382916C2781205201 @default.
• W3164382916 hasConceptScore W3164382916C2781253189 @default.
• W3164382916 hasConceptScore W3164382916C3008058167 @default.
• W3164382916 hasConceptScore W3164382916C3020803494 @default.
• W3164382916 hasConceptScore W3164382916C501593827 @default.
• W3164382916 hasConceptScore W3164382916C524204448 @default.
• W3164382916 hasConceptScore W3164382916C71924100 @default.
• W3164382916 hasConceptScore W3164382916C86803240 @default.
• W3164382916 hasConceptScore W3164382916C89423630 @default.
• W3164382916 hasConceptScore W3164382916C90924648 @default.
• W3164382916 hasIssue "Suppl 1" @default.
• W3164382916 hasLocation W31643829161 @default.
• W3164382916 hasOpenAccess W3164382916 @default.
• W3164382916 hasPrimaryLocation W31643829161 @default.
• W3164382916 hasRelatedWork W11823567 @default.
• W3164382916 hasRelatedWork W13335526 @default.
• W3164382916 hasRelatedWork W14708739 @default.
• W3164382916 hasRelatedWork W15672178 @default.
• W3164382916 hasRelatedWork W16726604 @default.
• W3164382916 hasRelatedWork W21025531 @default.
• W3164382916 hasRelatedWork W3515805 @default.
• W3164382916 hasRelatedWork W6371589 @default.
• W3164382916 hasRelatedWork W7920712 @default.
• W3164382916 hasRelatedWork W15760161 @default.
• W3164382916 hasVolume "80" @default.
• W3164382916 isParatext "false" @default.
• W3164382916 isRetracted "false" @default.
• W3164382916 magId "3164382916" @default.
• W3164382916 workType "article" @default.